

综述

错配修复基因和结肠癌的关系

马俊丽, 曾珊

中南大学湘雅医院肿瘤科, 长沙 410008

摘要:

错配修复系统(mismatch repair, MMR)是机体DNA修复机制的一种形式, 主要纠正碱基错配, 防止基因突变和维持基因组稳定性。miRNA介导的MMR表达异常和结肠癌的发生发展关系密切, MMR表达缺陷(dMMR)的结肠癌有独特的临床特征, 可以作为结肠癌的潜在预后及疗效预测因子。研究MMR与结肠癌的发生、MMR与miRNA的相互关系及MMR疗效预测等具有非常重要的意义。

关键词: 错配修复基因 微卫星不稳定性 miRNA 结肠癌

Relation between mismatch repair genes and colon cancer

MA Junli, ZENG Shan

Department of Oncology, Xiangya Hospital, Center South University, Changsha 410008, China

Abstract:

Mismatch repair (MMR) system is one form of DNA repair mechanisms, which plays an important role in rectifying the mismatch of base pairs, reducing gene mutations and keeping genome stability. Abnormal expression of MMR regulated by miRNA is closely related to the development of colon cancer. Functional defects of MMR (dMMR) with particular clinical characteristics can be used as a potential prognostic and predictive biomarker. This article reviews the relation between MMR system, miRNA and colon cancer.

Keywords: mismatch repair gene microsatellite instability miRNA colon cancer

收稿日期 2013-05-28 修回日期 网络版发布日期

DOI: 10.11817/j.issn.1672-7347.2014.02.014

基金项目:

国家自然科学基金(30770971, 30800518, 81102046, 81070362, 81172470); 湖南省自然科学基金(11JJ2049, 12JJ3118)。▼is work was supported by the National Natural Science Foundation (30770971, 30800518, 81102046, 81070362, 81172470) and the Natural Science Fund of Hunan Province, P. R. China (11JJ2049, 12JJ3118).

通讯作者: 曾珊, Email: zhengshan2000@yahoo.com

作者简介: 马俊丽, 硕士研究生, 医师, 主要从事消化道肿瘤方面的研究。

作者Email:

参考文献:

1. Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha [J]. Cell, 2013, 153(3): 590-600.
2. Yoon YS, Yu CS, Kim TW, et al. Mismatch repair status in sporadic colorectal cancer: immunohistochemistry and microsatellite instability analyses [J]. J Gastroenterol Hepatol, 2011, 26(12): 1733-1739.
3. Duraturo F, Cavallo A, Liccardo R, et al. Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of

扩展功能

本文信息

- ▶ Supporting info
- ▶ PDF(325KB)
- ▶ [HTML全文]
- ▶ 参考文献[PDF]
- ▶ 参考文献

服务与反馈

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ 引用本文
- ▶ Email Alert
- ▶ 文章反馈
- ▶ 浏览反馈信息

本文关键词相关文章

- ▶ 错配修复基因
- ▶ 微卫星不稳定性
- ▶ miRNA
- ▶ 结肠癌

本文作者相关文章

PubMed

- a novel alu-mediated deletion
[J]. *Biomed Res Int*, 2013, 2013: 219897.
4. Tomita N, Yamano T, Matsubara N, et al. A novel genetic disorder of Lynch syndrome – EPCAM gene deletion
[J]. *Gan To Kagaku Ryoho*, 2013, 40(2): 143-147.
5. Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and colorectal cancer prognosis
[J]. *J Clin Oncol*, 2005, 23(3): 609-618.
6. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer
[J]. *Expert Rev Gastroenterol Hepatol*, 2011, 5(3): 385-399.
7. Lin CC, Lai YL, Lin TC, et al. Clinicopathologic features and prognostic analysis of MSI-high colon cancer
[J]. *Int J Colorectal Dis*, 2012, 27(3): 277-286.
8. Wang L, Cunningham JM, Winters JL, et al. BF mutations in colon cancer are not likely attributable to defective DNA mismatch repair
[J]. *Cancer Res*, 2003, 63(17): 5209-5212.
9. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
[J]. *Clin Cancer Res*, 2008, 14(11): 3408-3415.
10. Han SW, Lee HJ, Bae JM, et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer
[J]. *Int J Cancer*, 2013, 132(9): 2209-2216.
11. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth
[J]. *Oncogene*, 2007, 26(19): 2799-2803.
12. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors
[J]. *Adv Exp Med Biol*, 2007, 604: 17-46.
13. Nagel R, le Sage C, Diosdado B, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer
[J]. *Cancer Res*, 2008, 68(14): 5795-5802.
14. Fodde R. e APC gene in colorectal cancer
[J]. *Eur J Cancer*, 2002, 38(7): 867-871.
15. Oberg AL, French AJ, Sarver AL, et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer
[J]. *PLoS One*, 2011, 6(6): e20465.
16. Sarver AL, French AJ, Borralho PM, et al. Human colon cancer proles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states
[J]. *BMC Cancer*, 2009, 9: 401.
17. Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma
[J]. *J Mol Diagn*, 2010, 12(4): 433-440.
18. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
[J]. *Mol Cancer*, 2007, 6: 54.
19. Zhong Z, Dong Z, Yang L, et al. MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells
[J]. *Tumour Biol*, 2013, 34(3): 1959-1965.
20. Svrcek M, El-Murr N, Wanherdrick K, et al. Overexpression of

- microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases
[J]. Carcinogenesis, 2013, 34(4): 828-834.
21. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155
[J]. Proc Natl Acad Sci USA, 2010, 107(15): 6982-6987.
22. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)
[J]. Proc Natl Acad Sci USA, 2010, 107(49): 21098-21103.
23. Tajima A, Iwaizumi M, Tseng-Rogenski S, et al. Both hMutSalpha and hMutSss DNA mismatch repair complexes participate in 5-uorouracil cytotoxicity
[J]. PLoS One, 2011, 6(12): e28117.
24. Donada M, Bonin S, Barbazza R, et al. Management of stage II colon cancer-the use of molecular biomarkers for adjuvant therapy decision
[J]. BMC Gastroenterol, 2013, 13: 36.
25. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy
[J]. Cancer Chemother Pharmacol, 2010, 66(4): 659-667.
26. Zaanani A, Flejou JF, Emile JF, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
[J]. Clin Cancer Res, 2011, 17(23): 7470-7478.
27. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer
[J]. Cancer Res, 2003, 63(18): 5738-5744.
28. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803
[J]. J Clin Oncol, 2009, 27(11): 1814-1821.

本刊中的类似文章

1. 刘合利¹, 晏仲舒¹, 廖国庆¹, 尹红玲², 谢小勇¹. 遗传性非息肉病性大肠癌30例临床病理特点与诊治分析[J]. 中南大学学报(医学版), 2009,34(08): 757-761
2. 蒋明¹, 徐龙¹, 赵毅¹, 方红辉², 陈朝晖³, 高原¹. 19号染色体微卫星杂合性缺失与原发胃癌的临床关系[J]. 中南大学学报(医学版), 2007,32(03): 455-459
3. 肖志明, 沈守荣, 连平, 王晓艳, 刘芬. 裸鼠脾脏移植瘤模型在NGX6抗结肠癌转移作用研究中的应用[J]. 中南大学学报(医学版), 2007,32(05): 753-757
4. 刘芬, 沈守荣, 李宏韬, 王晓艳, 彭娅, 廖曼甜, 郭勤. NGX6对Wnt/ β -catenin通路 β -catenin/TCF/LEF转录活化的影响[J]. 中南大学学报(医学版), 2007,32(06): 985-991
5. 李夏雨^{1,2}, 沈守荣², 武明花^{1,3}, 李小玲^{1,3}, 熊炜^{1,3}, 卢建红^{1,3}, 周鸣^{1,3}, 马健^{1,3}. 多基因遗传性肿瘤不同阶段转录组学调控规律及其分子机制[J]. 中南大学学报(医学版), 2011,36(7): 585-591
6. 刘芬, 沈守荣, 王晓艳, 等. 鼻咽癌相关基因6在人结肠癌Wnt/ β -catenin信号转导通路中的作用[J]. 中南大学学报(医学版), 2011,36(3): 235-
7. 裴海平, 黄林生, 刘利, 等. HSP27在左侧结肠癌和右侧结肠癌差异表达的实验研究[J]. 中南大学学报(医学版), 2011,36(4): 277-
8. 李新华, 张桂英, 李乾, 徐美华, 冯德云, 吴畏. 直肠癌组织异常表达miRNAs 的鉴定[J]. 中南大学学报(医学版), 2012,37(7): 662-668
9. 李楠, 李夏雨, 黄铄, 沈守荣, 王晓艳. miR-126靶向调控IRS1, SLC7A5及TOM1基因抑制结肠癌的增殖及侵袭转移[J]. 中南大学学报(医学版), 2013,38(8): 809-817